[Federal Register Volume 75, Number 67 (Thursday, April 8, 2010)]
[Notices]
[Pages 17924-17925]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-7891]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0174]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Applications for Food and Drug Administration Approval
to Market a New Drug: Patent Submission and Listing Requirements and
Application of 30-Month Stays on Approval of Abbreviated New Drug
Applications Certifying That a Patent Claiming a Drug is Valid or Will
Not Be Infringed
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on the reporting requirements for
submission and listing of patent information associated with a new drug
application (NDA), an amendment, or a supplement.
DATES: Submit written or electronic comments on the collection of
information by June 7, 2010.
ADDRESSES: Submit electronic comments on the collection of information
to http://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Elizabeth Berbakos, Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.,
PI50-400B, Rockville, MD 20850, 301-796-3792, e-mail:
[email protected].
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Applications for FDA Approval to Market a New Drug: Patent Submission
and Listing Requirements and Application of 30-month Stays on Approval
of Abbreviated New Drug Applications Certifying That a Patent Claiming
a Drug Is Invalid or Will Not Be Infringed (OMB Control Number 0910-
0513)--Extension.
Section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act (the
act) (21 U.S.C. 355(b)(1)) requires all NDA applicants to file, as part
of the NDA, ``the patent number and the expiration date of any patent
which claims the drug for which the applicant submitted the application
or which claims a method of using such drug and with respect to which a
claim of patent infringement could reasonably be asserted if a person
not licensed by the owner engaged in the manufacture[,] use, or sale of
the drug.'' Section 505(c)(2) of the act (21 U.S.C. 355(c)(2)) imposes
a similar patent submission obligation on holders of approved NDAs when
the NDA holder could not have submitted the patent information with its
application. Under section 505(b)(1) of the act, we publish patent
information after approval of an NDA application in the list entitled
``Approved Drug Products with Therapeutic Equivalence Evaluations''
(the Orange Book). If patent information is submitted after NDA
approval, section 505(c)(2) of the act directs us to publish the
information upon its submission.
FDA regulations at Sec. Sec. 314.50(h) (21 CFR 314.50(h)) and
314.53 (21 CFR 314.53) clarify the types of patent information that
must and must not be submitted to FDA as part of an NDA, an amendment,
or a supplement, and require persons submitting an NDA, an amendment,
or a supplement, or submitting information on a patent after NDA
approval, to make a detailed patent declaration using Form FDA 3542a
and Form FDA 3542.
The reporting burden for submitting an NDA, an amendment, or
supplement in accordance with Sec. 314.50 (a) through (f), and (k) has
been estimated by FDA and the collection of information has been
approved by OMB under OMB control number 0910-0001. We are not re-
estimating these approved burdens in this document. Only the reporting
burdens associated with patent submission and listing, as explained in
the following paragraphs, are estimated in this document.
The information collection reporting requirements are as follows:
Section 314.50(h) requires that an NDA, an amendment, or a
supplement
[[Page 17925]]
contain patent information described under Sec. 314.53.
Section 314.53 requires that an applicant submitting an NDA, an
amendment, or a supplement, except as provided in Sec. 314.53(d)(2),
submit on Forms 3542 and 3542a, the required patent information
described in this section.
Compliance with the information collection burdens under Sec. Sec.
314.50(h) and 314.53 consists of submitting with an NDA, an amendment,
or a supplement (collectively referred to as ``application'') the
required patent declaration(s) on Form 3542a for each ``patent that
claims the drug or a method of using the drug that is the subject of
the new drug application or amendment or supplement to it and with
respect to which a claim of patent infringement could reasonably be
asserted if a person not licensed by the owner of the patent engaged in
the manufacture, use, or sale of the drug product'' (Sec. 314.53(b)).
Such patents claim the drug substance (active ingredient), drug product
(formulation and composition), or method of use. If a patent is issued
after the application is filed with FDA but before the application is
approved, the applicant must submit the required patent information on
Form 3542a as an amendment to the application, within 30 days of the
date of issuance of the patent.
Within 30 days after the date of approval of an application, the
applicant must submit Form 3542 for each patent that claims the drug
substance (active ingredient), drug product (formulation and
composition), or approved method of use for listing in the Orange Book.
In addition, for patents issued after the date of approval of an
application, Form 3542 must be submitted within 30 days of the date of
issuance of the patent.
FDA estimates the burden of this collection of information as
follows:
Table 1.--Estimated Annual Reporting Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
No. of No. of Responses per Total Annual Hours per
21 CFR Section Sec. 314.50 (citing Sec. 314.53) Respondents Respondent Responses Response Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
Form FDA 3542a 233 2.6 606 20 12,120
--------------------------------------------------------------------------------------------------------------------------------------------------------
Form FDA 3542 154 2.6 400 5 2,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total Reporting Burden Hours: 14,120
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no operating and maintenance costs or capital costs associated with this collection of information.
The numbers of patents submitted to FDA for listing in the Orange
Book in 2007, 2008, and 2009 were 268, 347, and 335, respectively, for
an annual average of 317 (268 patents + 347 patents + 335 patents) / 3
years = 317 patents / year). Because many of these individual patents
are included in multiple NDA submissions, there could be multiple
declarations for a single patent. From our previous review of
submissions, we believe that approximately 14 percent of the patents
submitted are included in multiple NDA submissions, and thus require
multiple patent declarations. Therefore, we estimate that 44 (317
patents x 14 percent) patents will be multiple listings, and there will
be a total of 361 patents (317 patents + 44 patents = 361 patents)
declared on Form FDA 3542. We approved 67, 73, and 77 NDAs in 2007,
2008, and 2009, respectively, of which approximately 71% submitted
patent information for listing in the Orange Book. The remaining NDAs
submitted Form 3542 as required and declared that there were no
relevant patents. We also approved approximately 88, 96, and 62 NDA
supplements in 2007, 2008, and 2009, respectively, for which submission
of a patent declaration would be required. We estimate there will be
154 instances (based on an average of 72 NDA approvals and 82
supplement approvals per year) where an NDA holder would be affected by
the patent declaration requirements, and that each of these NDA holders
would, on average, submit 2.6 declarations ((361 patent declarations +
45 no relevant patent declarations) / 154 instances = 2.6 declarations
per instance) on Form FDA 3542. We filed 120, 113, and 118 NDAs in
2007, 2008, and 2009, respectively, and 145, 99, and 104 NDA
supplements in 2007, 2008, and 2009, respectively, for which submission
of a patent declaration would be required. We estimate there will be
233 instances (based on an average of 117 NDAs filed and 116 NDA
supplements filed per year) where an NDA holder would be affected by
the patent declaration requirements. We estimate, based on a
proportional increase from the number of declarations for approved
NDAs, that there will be an annual total of 606 declarations (233
instances x 2.6 declarations per instance = 606 declarations) on Form
FDA 3542a submitted with these applications. Based upon information
provided by regulated entities and other information, we previously
estimated that the information collection burden associated with Sec.
314.50(h) (citing Sec. 314.53) and FDA Forms 3542a and 3542 will be
approximately 20 hours and 5 hours per response, respectively.
On December 3, 2008, FDA announced in the Federal Register (73 FR
73659) the availability of a draft guidance for industry entitled
``Submission of Patent Information for Certain Old Antibiotics.'' That
draft guidance, if finalized, would provide information regarding FDA's
current thinking on the implementation of section 4(b)(1) of the Q1
Program Supplemental Funding Act (Public Law 110-379). Section 4(b)(1)
of the Q1 Act requires submission to FDA of patent information by
sponsors of certain NDAs containing old antibiotics. Estimates on the
number of Forms FDA 3542a and 3542 that might be submitted in
accordance with a finalized guidance have been included in table 1 of
this document.
Dated: April 2, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-7891 Filed 4-7-10; 8:45 am]
BILLING CODE 4160-01-S